First Trust Advisors LP Takes $3.11 Million Position in Cryolife Inc (CRY)

Share on StockTwits

First Trust Advisors LP acquired a new stake in Cryolife Inc (NYSE:CRY) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 109,655 shares of the medical equipment provider’s stock, valued at approximately $3,112,000. First Trust Advisors LP owned 0.30% of Cryolife as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Wells Fargo & Company MN boosted its position in Cryolife by 6.5% during the 3rd quarter. Wells Fargo & Company MN now owns 63,748 shares of the medical equipment provider’s stock worth $2,243,000 after acquiring an additional 3,905 shares during the last quarter. Monarch Partners Asset Management LLC boosted its position in Cryolife by 447.8% during the 4th quarter. Monarch Partners Asset Management LLC now owns 132,798 shares of the medical equipment provider’s stock worth $3,769,000 after acquiring an additional 108,558 shares during the last quarter. Capital Guardian Trust Co. acquired a new position in Cryolife during the 3rd quarter worth approximately $1,363,000. Bank of New York Mellon Corp boosted its position in Cryolife by 11.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 459,275 shares of the medical equipment provider’s stock worth $16,166,000 after acquiring an additional 48,994 shares during the last quarter. Finally, Capital International Investors acquired a new position in Cryolife during the 3rd quarter worth approximately $8,173,000. Institutional investors and hedge funds own 71.58% of the company’s stock.

In other news, Director Ronald D. Mccall sold 6,200 shares of the company’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $29.26, for a total transaction of $181,412.00. Following the sale, the director now owns 137,699 shares in the company, valued at approximately $4,029,072.74. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Amy Horton sold 6,666 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.15, for a total value of $194,313.90. Following the sale, the vice president now owns 103,713 shares in the company, valued at approximately $3,023,233.95. The disclosure for this sale can be found here. Corporate insiders own 3.97% of the company’s stock.

A number of equities analysts have weighed in on the company. Needham & Company LLC assumed coverage on Cryolife in a research report on Wednesday, February 27th. They set a “hold” rating and a $29.65 price target for the company. Zacks Investment Research raised Cryolife from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research report on Monday, February 4th. Northland Securities reaffirmed a “buy” rating and set a $32.00 price target on shares of Cryolife in a research report on Thursday, January 17th. Finally, ValuEngine raised Cryolife from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $32.16.

NYSE:CRY opened at $28.92 on Friday. Cryolife Inc has a twelve month low of $19.05 and a twelve month high of $36.05. The company has a debt-to-equity ratio of 0.81, a current ratio of 5.19 and a quick ratio of 3.87. The company has a market cap of $1.08 billion, a price-to-earnings ratio of 111.23 and a beta of 0.55.

Cryolife (NYSE:CRY) last announced its quarterly earnings data on Wednesday, February 13th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Cryolife had a positive return on equity of 3.49% and a negative net margin of 1.45%. The company had revenue of $67.80 million for the quarter, compared to the consensus estimate of $67.10 million. On average, sell-side analysts forecast that Cryolife Inc will post 0.31 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4222473/first-trust-advisors-lp-takes-3-11-million-position-in-cryolife-inc-cry.html.

Cryolife Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Further Reading: What is an Initial Public Offering (IPO)?

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Duke Energy  PT Set at $90.00 by JPMorgan Chase & Co.
Duke Energy PT Set at $90.00 by JPMorgan Chase & Co.
CNX Resources  Hits New 52-Week Low at $8.41
CNX Resources Hits New 52-Week Low at $8.41
Haymaker Acquisition  Coverage Initiated at Jefferies Financial Group
Haymaker Acquisition Coverage Initiated at Jefferies Financial Group
Tilly’s  Given a $18.00 Price Target at B. Riley
Tilly’s Given a $18.00 Price Target at B. Riley
Analyzing MoSys  and Ameri
Analyzing MoSys and Ameri
Zacks: Analysts Expect Lipocine Inc  to Announce -$0.22 EPS
Zacks: Analysts Expect Lipocine Inc to Announce -$0.22 EPS


© 2006-2019 Ticker Report